|
MechanismVoltage-gated sodium channels blockers |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date14 Dec 2017 |
|
Mechanismrenin inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date05 Mar 2007 |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.US |
First Approval Date18 Jan 2008 |
A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1
100 Clinical Results associated with Noden Pharma DAC
0 Patents (Medical) associated with Noden Pharma DAC
100 Deals associated with Noden Pharma DAC
100 Translational Medicine associated with Noden Pharma DAC